Genetic
BIIB111
BIIB111 is a genetic therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed267%
enrolling_by_invitation133%
Recent Activity
0 active trials
Showing 3 of 3
enrolling_by_invitationphase_3
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
NCT03584165
completedphase_2
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
NCT03507686
completedphase_3
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
NCT03496012
Clinical Trials (3)
Showing 3 of 3 trials
NCT03584165Phase 3
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
NCT03507686Phase 2
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
NCT03496012Phase 3
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3